Hosted on MSN19d
MAIA’s lung cancer therapy 99% more likely to improve OS over chemo alone
A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...
Cure Today14d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.
Yahoo Finance20d
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...
Investing20d
MAIA Biotechnology rapporteert veelbelovende THIO-onderzoeksresultaten voor NSCLC
CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), een biofarmaceutisch bedrijf in de klinische fase met een marktkapitalisatie van $49,4 miljoen, heeft bijgewerkte gegevens vrijgegeven van zij ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...